Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

However, the program itself is not covered by insurance. Available Ozempic alternatives: Wegovy, Zepbound, and Saxenda. Keep in mind that location, eligibility criteria, medical history ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

NVO’s arch-rival, Lilly, markets tirzepatide, a dual GIP and GLP-1 receptor agonist, as Mounjaro for T2D and Zepbound for obesity ... and strict regulations for insurance coverage have resulted ...

Zepbound was approved to treat sleep apnea after clinical trials found that patients taking the drug with or without traditional sleep apnea treatments, like a mask, experienced a reduction in ...

Lilly has been offering the vials only to patients paying on their own without insurance, also known as self-pay. Ricks said that about one in three or one in four patients on Zepbound are using ...

EPS will nearly double in 2024 to $13 and surge further in 2025 to nearly $23 as profits surge from Mounjaro and Zepbound sales soaring without the need to increase operating expenses. The massive ...

Lilly has been offering the vials only to patients paying on their own without insurance, also known as self-pay. Ricks said that about one in three or one in four patients on Zepbound are using ...